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SPECIFIC binding sites for the anti-inflammatory pro-
tein annexin I have been detected on the surface of
human  monocytes  and  polymorphonuclear  leuko-
cytes (PMN). These binding sites are proteinaceous in
nature and are sensitive to cleavage by the proteolytic
enzymes trypsin, collagenase, elastase and cathepsin
G. When monocytes and PMN were isolated independ-
ently  from  peripheral  blood,  only  the  monocytes
exhibited  constitutive  annexin  I  binding.  However
PMN acquired the capacity to bind annexin I follow-
ing co-culture with monocytes. PMN incubation with
sodium azide, but  not  protease inhibitors, partially
blocked this process. A similar increase in annexin I
binding capacity was also detected in PMN following
adhesion to endothelial monolayers. We propose that
a juxtacrine activation rather than a cleavage-medi-
ated transfer is involved in this process. Removal of
annexin I binding sites from monocytes with elastase
rendered monocytes functionally insensitive to  full
length annexin I or to the annexin I-derived pharma-
cophore, peptide Ac2–26, assessed as suppression of
the  respiratory  burst.  These  data  indicate  that  the
annexin I binding site on phagocytic cells may have
an important function in the feedback control of the
inflammatory response and their loss through cleav-
age could potentiate such responses.
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Introduction
Annexin I (also called lipocortin 1) is a member of a
family of calcium and phospholipid-binding proteins
termed ‘annexins’,  particularly  abundant  in  human
and  animal  leukocytes.  A  combination  of  Western
blotting,  ELISA  and  flow  cytometry  analyses  have
found high levels of this protein in monocytes and
polymorphonuclear leukocytes (PMN) whereas lower
amounts were detected in lymphocytes.1–3 Annexin I
levels in circulating leukocytes are partially under the
control of endogenous and exogenous glucocorticoid
hormones. A single  administration of  anti-inflamma-
tory steroids to human volunteers and experimental
animals  increases  annexin  I  levels  associated  with
circulating  leukocytes.1,4,5 Conversely  removal  of
endogenous  corticosterone  by  means  of  adrena-
lectomy  or  subchronic  treatment  with  a  steroid
antagonist, mifepristone  (RU486),  reduces  cell-asso-
ciated annexin I levels by ‡  50%.5,6
Recent  observations  have  substantiated  the  role
played by annexin I as a mediator of anti-inflamma-
tory  glucocorticoid  hormones.  Glucocorticoid-
dependent annexin I externalization has been demon-
strated  in  monocytes,  macrophages  and  PMN.4,7,8
Consistent with this, treatment of experimental ani-
mals  with  anti-annexin  I  antibodies  prevented  the
anti-inflammatory effect of dexamathasone in several
models  of  acute  inflammation.9,10 Besides  gluco-
corticoid  treatment,  we  and  others  have  recently
shown  that  annexin  I  secretion  from  human  PMN
occurs during the process of extravasation outside the
blood  vessel.11,12 Much  evidence  now  exists  to
support the hypothesis that annexin I interacts with
the external face of the leukocyte plasma membrane
to  exert  its  anti-inflammatory  properties,  such  as
inhibition of superoxide anion generation from acti-
vated monocytes.13
Recent studies have brought to light the existence
of specific annexin I binding molecule(s) on the cell
surface  of  peripheral  blood  leukocytes  and  several
other mono-myelocytic cell  lines.14 Incubation of a
mixed  population  of  peripheral  blood  leukocytes
with different concentrations of annexin I resulted in
a calcium-dependent and saturable binding to mono-
cytes and PMN, but not to ad-mixed lymphocytes.15
Monocyte binding capacity has been studied further,
observing  its  sensitivity  to  trypsin  treatment.  In
addition, monocytes lose annexin I binding capacity
following  incubation  at  37°C  in  a  time-dependent
manner.15 Further to our initial observations, specific
annexin I binding to a subset of human T-lymphocytes
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described.16,17
Here we extend our previous observations. It was
postulated that annexin I binding to leukocytes could
be  related  to  the  anti-inflammatory  profile  of  the
protein,  and  that  this  could  be  modulated  by  the
status  of  activation  of  the  cells.  To  address  this
hypothesis  we  have  investigated  (i)  the  extent  of
annexin I binding to monocytes and PMN in relation
to culture conditions, (ii) the susceptibility of annexin
I binding to proteolytic enzymes, (iii) the connection
between annexin I binding to monocytes and inhibi-
tion the respiratory burst.
Materials and methods
Leukocyte preparation and handling
Human peripheral blood was obtained from healthy
volunteers  by  venepuncture.  Healthy  donors  were
selected on the basis of having no current illnesses
nor  receiving  any  form  of  medication.  On  average
between 60ml and 100ml of blood was collected into
3.2% sodium citrate (10% v:v). Blood was diluted 1:1
with  sterile  phosphate-buffered  saline  (PBS)  and
separated  on  a  discontinuous  histopaque  gradient
(1077/1119) and centrifuged at 400 3 g for 30min at
room  temperature.  Peripheral  blood  mononuclear
cells (PBMC) and PMN layers were collected and cells
washed  three  times  in  PBS.  Erythrocytes  were
removed by hypotonic lysis in cold water. Finally, cells
were resuspended in 1ml RPMI 1640 medium supple-
mented with 0.2% BSA and 1.8mM CaCl2 (RBC). Cell
aliquots  were  counted  following  1:10  dilution  in
Turk’s  solution  using  a  haematocytometer.  PMN
population purity was >97% with a distinct popula-
tion being identified on the basis of the side scatter
profile;  in  addition this  population  was  CD14  neg-
ative. PMN contamination in the PBMC pellet was less
than  3%. A  discrete  monocyte  population  was  dis-
cerned by positivity for CD14.
Annexin I binding assay and flow cytometry
analysis
Cells were resuspended at 50 3 106 cells/ml in RPMI
1640 containing 0.2% BSA (bovine serum albumin) and
1.8mM CaCl2 (RBC) and 20m l aliquots were added to
96-well plates (Falcon) and incubated for 1h at 4°C
with 20m 1 human recombinant full length annexin I at
final  concentrations  ranging  from  10ng/ml  to
60m g/ml. The annexin I was prepared in PBC (PBS
containing 0.2% BSA and 1.8mM CaCl2). Cells were
then washed twice with PBC prior to addition of 20m l
human IgG (15mg/ml in PBC) to block non-specific
sites and 20m l of a specific murine anti-human annexin
I monoclonal antibody (mAb) 1B (60m g/ml in PBC)
and 1h incubation at 4°C. Finally, cells were washed in
PBC and incubated with 40m l (1:30 dilution in PBC) of
a F(ab9 )2 fragment of a goat anti-mouse IgG conjugated
to FITC. After a further 30min incubation at 4°C the
cells were washed and fixed in 1% paraformaldehyde.
Samples were analysed within 48h by flow cytometry
(FACScan, Becton Dickinson, Oxford, UK). Cell pop-
ulations  were  identified  by  their  forward  and  90°
scatter  characteristics,  and  fluorescence  associated
with each population (monocytes within the PBMC
population,  and  PMN)  was  quantified  in  the  FL1
channel. Cell-associated mean fluorescence intensity
was converted into second antibody molecules bound
per cell according to a calibration curve using standard
fluorescence beads.18
As  alluded  to  in  previous  publications,15,19 this
indirect methodology to assess annexin I binding to
leukocytes  was  developed  because  radiolabelling
protocols were found to be unsuitable for the protein,
which  degrades  upon  radiolabelling  and  does  not
retain either binding capacity or biological activity. An
estimation of binding affinity was also made using a
flow cytometric approximation of Scatchard analysis,
in  which  free  annexin  I  is  calculated  from  total
annexin I added to each tube less the amount bound
to the cells.
In  selected  experiments  monocyte  populations
were enriched (>80% pure) by NycoprepTM gradient
centrifugation (Nycomed Pharma AS, Oslo, Norway),
and  no  difference  was  observed  in  the  extent  of
annexin  I  binding  to  enriched  monocytes  when
compared  with  monocytes  ad-mixed  with  lympho-
cytes in the PBMC preparation (data not shown). For
this reason thereafter monocytes were prepared as
PBMC.
In some experiments additional cell surface mark-
ers on the monocyte plasma membrane were mon-
itored  with  an  anti-CD11b,  anti-CD14  or  an  anti-
CD54mAb.  AllmAb  were  used  at  a  5m g/ml  final
concentrations and incubated with the cells prior to
staining  with  the  F(ab9 )2 fragment  of  a  goat  anti-
mouse IgG conjugated to FITC (see above).
Selected samples were  also analysed by  confocal
microscopy.  FITC-stained  cells  were  fixed  with  a
equal  volume  of  2%  paraformaldehyde  in  PBS  and
pelleted.  Propidium  iodide  (PI)  was  added  as  a
nuclear  counterstain and  cells  were  mounted  onto
glass  slides  and  sealed  with  cover  slips.  A  BioRad
MRC600  confocal  microscope  system  with  1003
objective  lens,  100mW  argon  ion  laser  with  an
excitation  line  of  488nm  and  COMOSTM analysis
software was used to scan the samples and generate
TIF format images.
Cell treatment and incubation conditions
Effect  of  PMN:  monocyte  co-incubation.  PMN and
monocyte populations isolated from peripheral blood
were washed, counted and adjusted to 5 3 107 cells/
H. S. Euzger et al.
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were  co-incubated  in  polypropylene  tubes.  At  the
same  time,  PMN  and  monocytes  were  incubated
separately. After a 15min incubation period at room
temperature,  20m l  of each treatment group  (PMNs
alone, monocytes alone and a mixed population of
the two) were plated into each well (in duplicate). In
some cases, either PMN or PBMC were treated with or
without 0.2% sodium azide for 30min at 37°C prior to
15min co-incubation at room temperature.
Effect of leukocyte: endothelial cell co-incubation.
Potential variation(s) in annexin I binding capacity of
human PMN or monocytes was tested in an experi-
mental system in which cell-cell interactions certainly
occur. As recently described,11 EA.hy926 cells20 were
grown to confluence in 6-well  plates in DMEM-F12
supplemented  with  10%  FCS  and  antibiotics. After
washing,  1.5  3 106 PMNs  were  added  in  1ml
adhesion  medium  (Hanks’s  balanced  salt  solution
containing  0.2%  BSA,  1.3mM  CaCl2 and  MgCl2;  all
reagents from Sigma Chemical Co., Poole, UK)  and
incubated with 0.1m M platelet-activating factor (PAF)
was used as a stimulus to increase the extent of cell
adhesion.21 After  30min,  non-adherent  leukocytes
were  aspirated  whereas  adherent  cells  (PMNs  +
EA.hy926  or  monocytes  +  EA.hy926  cells)  were
removed using 1ml of non-enzymatic cell dissociation
medium (Sigma).
Effect  of  protease  inhibitors.  In  another  set  of
experiments  the  annexin  I  binding  capacity  of  a
mixed population containing equal numbers of PMNs
and  monocytes were  assessed following  incubation
with  either cell  type  the  specific  elastase inhibitor
ONO-5046  (10m M)  or  a  cocktail  of  protease  and
phosphatase inhibitors (phenylmethylsulphonyl fluo-
ride  (PMSF)  1mM,  leupeptin  0.2mM,  aprotinin
0.2mM and trypsin inhibitor 1mg/ml) for 30min in a
water bath at 37°C.
Effect of proteases. The effect of purified inflamma-
tory proteolytic enzymes on the extent of annexin I
binding was also evaluated. Type I collagenase (0.05,
0.5 and 5U/ml), neutrophil-derived cathepsin G (1,
10 and 100m g/ml), neutrophil-derived elastase (1, 10
and 100m g/ml) or soybean trypsin (250m g/ml) were
added to the cells in polypropylene tubes at 37°C up
to  30min.  In  some  experiments  elastase  was  co-
incubated with 10m M ONO-5046, a selective catalytic
inhibitor.  At  the  end  of  the  incubation  period,
proteolytic activity was removed by washing the cells
twice in RPMI 1640 containing 4% BSA and 1.8mM
CaCl2. Monocytes were subsequently washed once in
protein-free RPMI 1640 and resuspended in RBC.
Effect of monocyte supernatants. Monocytes were
incubated with or without 10m g/ml human elastase
for 30min at 37°C. Reaction was stopped by a 5min
addition of 30m M ONO-5046 followed by centrifuga-
tion  at  2000  r.p.m.  for  5min.  Supernatants  were
collected  and  co-incubated  with  control  PMNs  for
20min at 37°C. Cells were spun once more prior to
performing the annexin I binding assay.
Effect of monocyte or PMN activation. The effect
of  monocyte  or  PMN  activation  on  the  annexin  I
binding capacity displayed by each cell type was also
investigated. For this purpose monocytes were incu-
bated with 100ng/ml monocyte chemotactic protein-
1  (MCP-1)  and  PMNs  were  activated  with  0.1m M
platelet-activating factor (PAF), 1m M FMLP or 0.1m M
phorbol 12-myristate 13-acetate (PMA).
At the end of all these different treatments, cells
were thoroughly washed in PBC, resuspended in RBC
(20m l per 106 cells) and the annexin I binding assay
performed as described above.
Measurement of respiratory burst activity
Production of reactive oxygen species from activated
monocytes  was  measured  using  the  fluorochrome
dihydrorhodamine  6G  according  to  the  manufac-
turer’s indications. Monocytes isolated from periph-
eral  blood  were  adjusted to  2.5  3 106 cells/ml  in
PBSGC  (PBS  containing  0.9%  glucose  and  1mM
CaCl2). Aliquots (200m l) were incubated with 5mM
dihydrorhodamine 6G for 10min in a water bath at
37°C. After  the  incubation  period monocytes were
challenged with 0.1m M PMA or 1mg/ml opsonized
zymosan for 10min. The time and the concentrations
were chosen on the basis of preliminary experiments.
Opsonized  zymosan  was  prepared  by  incubating
10mg  of  boiled  zymosan  A  with  1ml  of  serum
(prepared from the same donor) for 30min in a water
bath at 37°C, followed by two washes in PBSGC in a
microfuge  (3min  at  13000  r.p.m).  After  the  final
incubation period the reaction was stopped by adding
a final concentration of 0.2% sodium azide, this being
followed by immediate incubation of cells on ice, and
analysis by flow cytometry.
The  biological  efficacy  of  full  length  annexin  I
purified  from  human  placenta  and  the  annexin
I-derived peptide Ac2–2622,23 on  this  parameter  of
monocyte activation was then related to the binding
capacity displayed by the cell. Human native annexin
I (0.3–5m g/ml) or peptide Ac2–26 (1–10m g/ml) were
added  to  the  cells  for  30min  prior  to  monocyte
stimulation  for  a  further  10min  with  either  PMA
(0.1m M) or opsonized zymosan (1mg/ml). Also, the
ability of annexin I and peptide Ac2–26 to suppress
the  respiratory  burst  was  monitored in  monocytes
pretreated  with  100m g/ml  elastase  (30min,  37°C),
with  the  proteolytic  activity  being  quenched  with
10m M ONO-5046  prior to washing and addition of
peptide Ac2–26 (1m g/ml) or annexin I (3m g/ml).
Materials
Human annexin I andmAb IB,24 used for the binding
assays,  was  provided  by  Dr  J.L.  Browning  (Biogen
Annexin I binding and monocyte activation
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active  full  length  native  annexin  I  (used  for  the
superoxide experiments) was purified from placenta
and  generously  supplied  by  Dr  E.  Solito  (INSERM,
Paris, France). Human Ac2–26 (N-acetyl- AMVSEFLK-
QAWFIENEEQEYVQTVK; Mr of 3050 Da, prepared at
the Advance Biotechnology Centre, The Charing Cross
and Westminster Medical School, London, UK) corre-
sponds to a sequence comprising the majority of the
human annexin I N-terminus region. The peptide was
prepared by use of solid phase step-wise synthesis:
amino acid composition and molecular weight were
verified by mass spectrometry, and purity (=95%) was
assessed by HPLC and capillary electrophoresis (data
from  manufacturer).  Peptide solutions  were  always
prepared in sterile PBS.
ONO-5046,  a  selective  leukocyte  elastase  inhib-
itor,25 was  provided  by  ONO  Pharmaceutical  Co.
(Osaka, Japan). Neutrophil-derived cathepsin G and
elastase  were  from  Calbiochem  (Nottingham,  UK).
Dihydrorhodamine  6G  was  from  Molecular  Probes
(Eugene,  USA).  Monoclonal  antibodies  anti-human
CD11b  (clone  44),  anti-human  CD14  (clone  AML-
2.23)  and an anti-human CD54 (clone BC-14)  were
from  Serotec  Ltd  (Oxford,  UK).  Beads  bearing  a
known number  of  FITC molecules were purchased
from  Flow  Cytometry Standards Co. (San Juan, PR,
USA). Human MCP-1 protein was obtained from R&D
Systems (Abingdon, UK).
Type  I  collagenase  (from  Clostridium  histolyti-
cum), soybean trypsin, zymosan A, PMA, FMLP and all
other reagents were from Sigma Chemical Co. (Poole,
Dorset, UK).
Statistics
Data are reported as mean ± SEM of n experiments
performed  in  duplicate  or  triplicate.  Approximate
affinity constants (Kd) and maximal binding (Bmax)
were determined using an flow cytometric approx-
imation of Scatchard analysis. Briefly, in a seven point
Scatchard plot, number of mols of free ligand were
calculated  as  total  mols  added minus  mols  bound.
Statistical differences between groups were analysed
by analysis of variance followed by Bonferroni’s test
for post-hoc comparisons, or  by  two-way Student’s
t-test when only two groups were analysed using the
Instat™ software. In all cases, a P value less than 0.05
was taken as the limit of significance.
Results
Monocytes and PMNs bind annexin I
When  purified  separately,  human  monocytes  dis-
played  a  reproducible  and  significant  annexin  I
binding  capacity  whereas  enriched  preparations
(>95%  pure)  of  PMN  exhibited  negligible  binding
(Fig.  1a).  However,  significant  changes  in  binding
capacities were found when the binding  assay was
performed with both cell types in co-culture (15min
at room temperature). Figure  1a illustrates  a  repre-
sentative experiment where monocytes lost approx-
imately  40%  of  annexin  I  binding  capacity  if  co-
cultured with PMN, and conversely the latter cell type
acquired the capacity to bind annexin I. Cumulative
data of n = 8 distinct experiments showed 42 ± 5%
reduction  of  the  extent  of  annexin  I  binding  in
monocytes  which  had  been  co-cultured  with  the
PMN. In the same of set of experiments, PMN showed
a substantial increase in annexin I binding such that
20700 ± 2700 binding sites per cell were detected
after  co-incubation  compared  with  2300  ±  600
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FIG. 1. Annexin I binding capacity and affinity of isolated and
co-incubated monocytes (M) and polymorphonuclear leuko-
cytes (P). Panel (a): Equal numbers of M and P were either co-
incubated at room temperature for 15min, or left separate,
prior to washing and quantification of the annexin I binding
capacity as described in the Experimental section. Data are
mean ± SEM of one experiment performed in triplicate and
are representative of four distinct experiments with similar
results.  Panel  (b):  Estimation  of  the  dissociation  constant
(Kd)  of  annexin  I  binding  by  flow  cytometry.  Scatchard
approximation  as  described  in  the  Experimental  section.
Data are mean ± SEM as above.binding  sites  quantified  in  absence  of  monocytes
(using  a  saturating  annexin  I  concentration  of
20m g/ml). Analyses of approximate affinity constant
and total number of binding sites from four experi-
ments performed with all annexin I concentrations
are depicted in  Fig.  1b. The following  values  were
obtained:  monocytes  bound  annexin  I  with  an
approximate  Kd  of  48nM  and  a  Bmax  of  60200
annexin I molecules per cell. Bmax but not Kd was
reduced after incubation with PMN, at 37700 binding
sites  per  cell. The  parameters  for  PMN  were  also
Annexin I binding and monocyte activation
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FIG.  2.  Confocal  images  of  peripheral  blood  monocytes
demonstrating the punctate distribution of annexin I binding
to the cell surface. The pattern of annexin I binding to two
distinct  monocytes  is  shown  (green  fluorescence).  See
Experimental  section  for  details  of  staining  and  confocal
analysis.
FIG.  3.  Effect  of  several  agents  on  annexin  I  binding
capacity displayed by isolated and co-incubated monocytes
(M) and polymorphonuclear leukocytes (P). Panel (a): M or
P were treated separately with control buffer (no azide) or
with 0.2% sodium azide for 30min at 37°C prior to 15min
co-incubation at room temperature. Cells were then washed
and  binding  capacity  assessed  using  20m g/ml  annexin  I.
Data are mean ±  SEM of eight experiments performed in
duplicate. *P < 0.05 as calculated on original values. Panel
(b): Equal numbers of M and P were either kept separate,
mixed together in the absence or presence of 10m M ONO-
5046 at room temperature for 30min prior to washing and
quantification  of  the  annexin  I  binding  capacity  (with
20m g/ml annexin I). Data are mean ± SEM of three experi-
ments performed in duplicate. Panel (c) as in panel B with
the  difference  that  a  cocktail  of  inhibitors  (PMSF  1mM,
leupeptin  0.2mM,  aprotinin  0.2mM  and  trypsin  inhibitor
1mg/ml) was used. Data are mean ± SEM of three experi-
ments performed in duplicate.analysed after co-incubation with the monocytes with
an approximate Kd of 47nM and a Bmax of 19700
annexin I molecules per cell.
Expression  of  another  surface  protein  following
monocyte  and  PMN  co-incubation  was  also  mon-
itored. High levels of the CD14 antigen were found on
isolated monocytes (293 200 ± 46000 sites per cell)
whereas much lower levels were detected on freshly
isolated PMNs (4800  ±  1200  sites  per  cell). These
values  remained  essentially  unaltered  following  co-
incubation, with 297700 ± 32200 and 5039 ± 2200
CD14 antigen sites per cell on monocytes and PMNs,
respectively  (data  are  mean  ±  SEM  of  n =  3
experiments performed in triplicate).
The appearance of annexin I binding was investi-
gated by confocal microscopy. Figure  2 shows that
exogenous  annexin  I  bound  to  monocytes  with  a
punctuate distribution on the cell surface. A similar
pattern  was  also  visualized  on  the  PMN  following
incubation with monocytes (data not shown).
Next, we attempted to characterize the process by
which  monocytes  and  PMN  respectively  lost  and
gained annexin I binding capacity. Pre-incubation of
PMN with sodium azide prior to co-incubation with
the mononuclear cells  prevented the acquisition  of
annexin  I  binding  capacity  by  the  PMN  without
altering the reduced binding capacity of the mono-
cytes  (Fig.  3a).  Pre-incubation  of  monocytes  with
sodium  azide  had  no  effect. Addition  of  a  specific
elastase inhibitor (ONO-5046) or of a mixture of non-
specific protease and phosphatase inhibitors failed to
prevent either the reduction in monocyte binding or
the PMN increase, in annexin I binding capacity (Fig.
3b and c).
Inflammatory proteases reduce annexin I
binding to monocytes
Incubation  of  monocytes  with  trypsin  abolished
subsequent cell binding to exogenous annexin I, thus
confirming previous observations.15 Figure 4 shows
that enzymes  normally  found  in  inflammatory  exu-
dates are also capable of reducing annexin I binding.
Incubation of monocytes with elastase, cathepsin G
or collagenase produced a significant reduction in the
number  of  annexin  I  binding  sites  (Fig.  4a).  The
specificity of elastase effect was validated by using a
selective  inhibitor  and  addition  of  ONO-5046  pre-
vented  the  loss  of  annexin  I  binding  by  elastase
treatment (Fig. 4b).
The efficacy of elastase prompted the cell transfer
experiment.  Addition  to  PMNs  of  a  supernatant
derived  from  elastase-treated monocytes  (in  which
the enzymatic activity had be quenched with ONO-
5046)  did not promote annexin I binding capacity:
3900 ± 950 and 3200 ± 640 annexin I binding sites
per cell were measured after PMN incubation with an
elastase-treated  monocyte  supernatant  and  control
monocyte supernatant, respectively (mean ± SEM of n
= 2 experiments performed in triplicate).
The possibility that elastase, which binds to leuko-
cyte  plasma  membrane,26 could  interfere  with  the
binding by cleaving the ligand,27 was also taken into
account.  Not  only  was  ONO-5046  added  to  the
incubation mixture prior to performing the annexin I
binding assay (reported to block elastase activity in
Fig.  4b),  but  also  an  annexin  I  preparation  fully
cleaved  by  elastase  was  tested.  This  preparation
(33Kd  isoform)  produced  a  curve  of  binding  to
monocytes  comparable  with  that  obtained  using
intact full length annexin I. For instance, 24400 ± 170
and  24500  ±  300  annexin  I  molecules  bound  per
monocyte  were  found  following  incubation  with
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FIG. 4. Susceptibility of annexin I binding capacity displayed
by human monocytes to inflammatory proteolytic enzymes.
Monocytes were incubated with the reported concentrations
of  collagenase or  cathepsin G  (panel a), elastase ± 10m M
ONO-5046  (panel  b)  for  30min prior  to  incubation with  a
saturable  concentration  of  annexin  I  (10m g/ml).  Data  are
mean  ±  SEM  of  seven  experiments  (panel  a)  and  six
experiments (panel b) performed in duplicate. *P < 0.05.20m g/ml  intact  full  length  annexin  I  or  elastase-
cleaved annexin I, respectively.
PMN, monocytes and endothelial cell
interaction
Figure 5a shows that the modest annexin I binding
capacity  displayed  by  freshly  prepared  PMNs  was
greatly  increased following  adhesion  to  endothelial
monolayers. This increase was  not modified to any
extent by cell-derived proteases which are likely to be
present  in  this  microenvironment,  since  a  similar
degree of annexin I binding was also attained when a
mixture  of  non-specific  protease  inhibitors  (see
above)  was  added  to  the  adhesion  medium:  this
cocktail of protease inhibitors was internally validated
since it prevented the reduced binding of annexin I to
post-adherent  endothelial  cells  (data  not  shown).
When  monocytes  were  used  in  the  same  experi-
mental procedure, a significant (~50%) reduction in
annexin  I  binding  capacity  was  displayed  by  post-
adherent cells (Fig. 5b).
Effect of leukocyte activation
PMN activation either with 0.1m M PAF, 1m M FMLP or
1m M  PMA  did  not  modify  the  annexin  I  binding
capacity  displayed  by  this  cell  type  (Fig.  6).  As
expected,  co-incubation  of  PMNs  with  monocytes
increased annexin I binding to the neutrophils, and
this  was  used  as  a  positive  control  in  this  set  of
experiments.  Similarly,  monocyte  activation  with
100ng/ml MCP-1 did not cause any reduction on the
extent  of  annexin  I  binding  to  the  cells  (data  not
shown).
Biological significance of annexin I binding to
human monocytes
Monocyte incubation with opsonized zymosan (1mg/
ml)  or  PMA (0.1m M)  produced a  respiratory burst
quantified by flow cytometry (Fig.  7a). This release
was  selectively  inhibition  by  annexin  I.  Figure  7b
shows  a  steep  concentration-dependent  curve  for
annexin  I inhibition  with  a  maximal  effect  ranging
between 20% and 30% at 3m g/ml. Annexin I inhibi-
tory  action  was  specific  because  the  protein  was
unable to alter monocyte respiratory burst when cells
were  activated with  PMA  (Fig.  7b). The  annexin  I
pharmacophore, peptide Ac2–26,  was  also  able  to
inhibit  superoxide  production  displaying  selectivity
towards opsonized zymosan (Fig. 7c).
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FIG. 5. Annexin I binding capacity in post-adherent PMNs
and monocytes. Panel (a): Freshly prepared PMN or untrea-
ted EA.hy926 cells  (open bars),  or  a mixture of  PMN  and
EA.hy926  cells  obtained  after  a  30min  adhesion  period
(hatched bars), were incubated with a saturating concentra-
tion  of  annexin  I  (10m g/ml).  Panel  b: Freshly  prepared
monocytes  or  untreated  EA.hy926  cells  (open  bars),  or  a
mixture  of  monocytes  and  EA.hy926  cells  (hatched  bars)
obtained  after  a  30min  adhesion  period,  were  incubated
with a saturating concentration of annexin I (10m g/ml). In all
cases,  data  are  mean  ±  SEM  from  three  experiment per-
formed in triplicate. *P < 0.05 vs. untreated cells.
FIG.  6.  Annexin  I  binding  is  not  acquired  by  stimulated
PMNs.  PMNs  were  left  untreated  or  were  stimulated  for
30min with PMA (1m M), PAF (0.1m M) or FMLP (1m M) prior to
incubation  with  a  saturating  concentration  of  annexin  I
(10m g/ml).  As  a  positive  control,  the  ‘gain’  of  annexin  I
binding to PMN which had been co-incubated with monocyte
(P + M group) was also monitored. Data are mean ± SEM of
three experiments performed in triplicate. *P < 0.05.Monocyte pre-treatment with elastase, a procedure
known to reduce significantly annexin I binding (see
Fig. 4), prevented the inhibitory action of annexin I
and peptide Ac2–26 on zymosan-induced superoxide
generation  (Fig.  7d).  The  efficacy  of  elastase  in
reducing  annexin  I  binding  was  also  monitored.
Binding was reduced by >95% following treatment of
monocytes  with  100m g/ml  elastase (n =  4  experi-
ments,  P <  0.05). The  elastase  effect  was  specific
because the enzyme did not alter the extent of CD11b
or CD54 expression on the monocyte plasma mem-
brane (117400 ± 8900 and 116200 ± 6200 CD11b
molecules per cell, and 6300 ± 300 and 6600 ± 300
CD54 molecules per cell in the absence or presence
of elastase, respectively).
Discussion
The main conclusion from this study is that annexin I
binding capacity expressed by resting monocytes is
proteinaceous  in  nature  and  can  be  dramatically
reduced following co-incubation with PMN. We also
present strong evidence that occupation of annexin I
binding sites on monocytes is a pre-requisite for the
inhibitory  biological  actions  exerted  by  this  anti-
inflammatory mediator.
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FIG. 7. Annexin I inhibition of respiratory burst of activated human monocytes is dependent on an intact binding site. Panel (a):
Monocytes (5 3 10
5) were incubated with 0.1m M PMA or 1mg/ml opsonized zymosan (ZYM) for the reported times prior to
flow cytometry. Data are mean ± SEM of eight experiments performed in duplicate. Monocytes (5 3 10
5) were incubated with
the reported concentrations of annexin I (panel b) or peptide Ac2–26 (panel c) for 30min prior to addition of 0.1m M PMA (open
circles) or 1mg/ml opsonized zymosan (ZYM; closed circles) for a further 10min. Data are mean ± SEM of five experiments
performed in duplicate (*P < 0.05 as calculated on original values). Panel (d): Monocytes were treated with or without 100m g/ml
elastase for  30min at 37°C.  Reactions  were stopped by adding 10m M  ONO-5046 and extensive washing in enzyme-free
medium. Cells were  then incubated  with annexin I  or  peptide Ac2–26 as  described  above and stimulated with 1mg/ml
opsonized zymosan to activate the oxidative burst. Data are mean ± SEM of five experiments performed in duplicate (*P < 0.05
as calculated on original values).As  previously  reported,15,19 human  monocytes
display a saturable annexin I binding capacity follow-
ing in vitro incubation with the human recombinant
protein.  Similarly,  we  confirmed  that  trypsin  treat-
ment of monocytes abolished their capacity to bind
annexin I, and have shown for the first time that this
binding  is  susceptible  to  the  action of  other more
specific proteolytic enzymes. Both collagenase, cath-
epsin G and elastase treatment of monocytes resulted
in almost complete loss of annexin I binding capacity.
This  is  unlikely  to  be  due  to  a  destruction  of  the
ligand,27 since (i)  cells  were extensively washed in
high BSA media; (ii) specific inhibitors were added to
block the catalytic site of the protease, as in the case
of elastase, and (iii) elastase-cleaved annexin I, gen-
erating a 33Kd isoform, was able to bind to mono-
cytes to a similar degree as intact annexin I.
However, this binding is vulnerable in the presence
of  PMN. In  previous  studies  PMN were  always  co-
incubated with monocytes in the binding assay, and
showed a binding capacity with a Kd similar to the
one calculated for monocytes.19 Using  purified cul-
tures,  two  distinct  processes  can  be  distinguished:
monocytes  (either  pure  or  together  with  lympho-
cytes), but not PMN, express constitutive annexin I
binding capacity, which however can be differentially
modified  in  co-culture  conditions.  PMN  acquired
annexin I binding  capacity only after co-incubation
with the monocytes, which in turn showed a compa-
rable degree of loss. A similar Kd could be calculated
for  both  cell  types.  On  this  basis,  we  suggest  that
annexin I binds to an identical ‘site’ on both leukocyte
types.
There are two potential ways by which the annexin
I binding sites on the two cell types could be altered:
either the binding  site is released (by a proteolytic
event)  in  the  culture  medium  and  adheres  to  the
PMN, or it is differentially expressed as a consequence
of  activation  phenomena  occurring  between  the
adjacent monocyte and PMN. Examples of the latter,
i.e. cell activation through a juxtacrine mechanism,
have been recently reported.28
Based  on  the  experimental  data  obtained,  we
believe that the first hypothesis is unlikely for at least
three  reasons.  Firstly,  despite  the  susceptibility
showed by the monocyte annexin I binding capacity
to proteolytic  enzymes,  the loss  observed after co-
incubation  with  the  PMNs  was  not  blocked  by  a
mixture of non-specific protease inhibitors or by the
specific elastase inhibitor ONO-5046. Secondly, addi-
tion to PMNs of a supernatant from elastase-treated
monocytes  was  without  effect.  Thirdly,  monocyte
activation  with  the  specific  chemoattractant  and
activator MCP-1 did not reduce the annexin I binding
capacity displayed by these cells. Similarly, PMNs did
not increase their capacity to bind annexin I following
incubation with PAF, FMLP or PMA. All these data rule
out  the  possibility  that  proteolytic  activities,  tran-
siently  exposed  on  the  PMN  plasma  membrane,26
could be responsible for this phenomenon.
However, an active role for the PMN was suggested
by the experiments with sodium azide. Blockade of
PMN, but  not monocyte, respiratory pathways pre-
vented the phenomenon of annexin I binding acquisi-
tion by the neutrophil without affecting the loss from
the monocyte. The hypothesis of a juxtacrine process
is  clearly  reinforced  by  the  experiments  of  PMN
interaction  with  endothelial  cells.  Adherent  PMNs
acquired a considerable binding capacity compared
to control cells. This was clearly due to the adhesion
process, and not to the addition of FMLP, since this
cell  activator  per  se is  totally  inactive  of  PMN  in
suspension. In this context, it is interesting to note
that following  PMN adhesion to  endothelial  mono-
layers, endogenous annexin I is externalized on the
surface  of  the  adherent  leukocytes.11 It  therefore
seems that the entire annexin I pathway can be fully
activated  at  the  interface  between  adherent  PMN/
endothelial cells.
In conclusion we propose that PMN co-incubation
with  monocytes results  in  acquisition  of  annexin  I
binding as a result of an active phenomenon due to a
juxtacrine  mechanism  and  involving  new  protein
expression  on  the  plasma  membrane.  It  remains
unclear  how  the  annexin  I  binding  protein  could
disappear from the monocyte plasma membrane. It
seems unlikely that this is the result of a proteolytic
process, but  further  studies are necessary to deter-
mine if this is the result of internalization following
juxtacrine activation in the presence of PMN.
Annexin  I  possesses  the  biological  profile  of  an
inhibitory protein with the ability to suppress selec-
ted  parameters  of  cell  activation,  including  super-
oxide anion generation and arachidonate, eicosanoids
and nitric oxide release.13,29,30 The annexin I-derived
N-terminus peptide, peptide Ac2–26, has been repor-
ted to inhibit arachidonate and elastase release from
activated PMNs21 and macrophage phagocytosis.31 In
the present study we report  for  the first  time  that
annexin  I, and its pharmacophore peptide Ac2–26,
must  interact  with  proteins  associated  with  the
monocyte plasma membrane in order to suppress cell
activation, measured as respiratory burst. The inhibi-
tion  was  stimulus-dependent,  such  that when  cells
were activated with PMA, which bypasses receptor-
mediated phenomena by activating intracellular pro-
tein kinases, no effect was exhibited by annexin I or
peptide Ac2–26. A maximal inhibition of 20–30% was
reached in this set of experiments which is similar to
that obtain with peptide Ac2–26 on murine macro-
phage  phagocytosis  using  the  same  protocol.31
Importantly, annexin I showed an approximate IC50
of  1.2m g/ml  (32nM)  which  is  close  to  the  Kd
calculated  from  the  binding  experiments.  Pretreat-
ment of monocytes with elastase did not affect the
extent  of  cellular  respiratory  burst  following  opso-
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surface  markers  (CD11b  and  CD54).  In  contrast,
elastase abrogated annexin  I binding  to monocytes
and similarly abolished the inhibitory action displayed
by annexin I or its N-terminus peptide. This strongly
suggests that annexin I binding to the protein(s) on
the monocyte plasma membrane15 is instrumental in
its inhibitory properties. In addition, peptide Ac2–26
action in an in vivo model of experimental inflamma-
tion was already proposed to require an interaction
with the annexin I binding site,22 and this hypothesis
in reinforced by the data here presented on activated
monocytes in vitro.
In conclusion, we report an exquisite sensitivity of
the annexin I binding protein(s) present on human
monocytes  to  the  phenomena  of  activation  and
provide strong  evidence that  the  binding  is  a  pre-
requisite to the anti-inflammatory action produced by
annexin I on this cell type.
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